Overview

A Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally to Subjects With Solid Tumors

Status:
Completed
Trial end date:
2011-08-29
Target enrollment:
Participant gender:
Summary
This clinical study is being conducted at two sites to determine the optimum dose, safety, and tolerability of GSK1363089 treatment in adults with solid tumors. This study is no longer recruiting subjects.
Phase:
Phase 1
Details
Lead Sponsor:
GlaxoSmithKline